Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) Equity Average (2020 - 2025)

Tango Therapeutics has reported Equity Average over the past 6 years, most recently at $253.1 million for Q4 2025.

  • Quarterly results put Equity Average at $253.1 million for Q4 2025, up 18.08% from a year ago — trailing twelve months through Dec 2025 was $253.1 million (up 18.08% YoY), and the annual figure for FY2025 was $272.8 million, up 20.56%.
  • Equity Average for Q4 2025 was $253.1 million at Tango Therapeutics, up from $147.5 million in the prior quarter.
  • Over the last five years, Equity Average for TNGX hit a ceiling of $355.1 million in Q4 2021 and a floor of $48.2 million in Q1 2021.
  • Median Equity Average over the past 5 years was $241.6 million (2023), compared with a mean of $226.5 million.
  • Biggest five-year swings in Equity Average: soared 730.51% in 2021 and later plummeted 41.09% in 2025.
  • Tango Therapeutics' Equity Average stood at $355.1 million in 2021, then dropped by 26.42% to $261.3 million in 2022, then increased by 1.37% to $264.9 million in 2023, then decreased by 19.07% to $214.3 million in 2024, then increased by 18.08% to $253.1 million in 2025.
  • The last three reported values for Equity Average were $253.1 million (Q4 2025), $147.5 million (Q3 2025), and $150.9 million (Q2 2025) per Business Quant data.